181 related articles for article (PubMed ID: 29130236)
1. [Occurrence, diagnosis and treatment of de novo gastrointestinal malignancies after organ transplantation].
Ji L; Zhao G
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1206-1210. PubMed ID: 29130236
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
4. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
5. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
Marcén R
Drugs; 2009 Nov; 69(16):2227-43. PubMed ID: 19852526
[TBL] [Abstract][Full Text] [Related]
7. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
9. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
Qin Y; Zhang F; Shen B; Liu Y; Qiu J; Guo Y; Fan Y
Int J Clin Pract Suppl; 2014 Apr; (181):17-22. PubMed ID: 24673715
[TBL] [Abstract][Full Text] [Related]
11. De novo sirolimus-based regimen in Thai renal transplant recipients.
Townamchai N; Avihingsanon Y; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
Transplant Proc; 2008 Sep; 40(7):2206-8. PubMed ID: 18790193
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial.
Schmeding M; Kiessling A; Neuhaus R; Heidenhain C; Bahra M; Neuhaus P; Neumann UP
Transplantation; 2011 Oct; 92(8):923-9. PubMed ID: 21832958
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of early withdrawal of calcineurin inhibitors in kidney transplant recipients 6 months' posttransplant.
Boswell A; Evans L; Rigg K; Shehata M
Transplant Proc; 2005 Mar; 37(2):884-5. PubMed ID: 15848564
[TBL] [Abstract][Full Text] [Related]
14.
Manzia TM; Angelico R; Gazia C; Lenci I; Milana M; Ademoyero OT; Pedini D; Toti L; Spada M; Tisone G; Baiocchi L
World J Gastroenterol; 2019 Sep; 25(35):5356-5375. PubMed ID: 31558879
[TBL] [Abstract][Full Text] [Related]
15. Hot-topic debate on kidney function: renal-sparing approaches are beneficial.
Durand F
Liver Transpl; 2011 Nov; 17 Suppl 3():S43-9. PubMed ID: 21796759
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.
Kamar N; Del Bello A; Belliere J; Rostaing L
Transpl Int; 2015 Aug; 28(8):928-37. PubMed ID: 25557802
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
18. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
19. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
20. Everolimus: preventing organ rejection in adult kidney transplant recipients.
Dantal J
Expert Opin Pharmacother; 2012 Apr; 13(5):767-78. PubMed ID: 22404500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
